Diagnostic accuracy of Immulite (R) TSI immunoassay for thyroid-associated orbitopathy in patients with recently diagnosed Graves' hyperthyroidism

Purpose The Immulite (R) thyroid stimulating immunoglobulin (TSI) immunoassay is a relatively new commercial assay that has shown good diagnostic accuracy in Graves' hyperthyroidism (GH). However, its clinical utility in thyroid-associated orbitopathy (TAO) is less clear. The purpose of this study was to assess the diagnostic accuracy of the Immulite (R) TSI immunoassay for TAO and investigate the associations between TSI and other clinical measures. Methods One hundred and forty patients that had been diagnosed with GH within the previous 12 months were recruited. Identification and grading of TAO were performed at enrolment and serum samples were analysed using the Immulite (R) TSI immunoassay. Results Of the 140 participants recruited, 75 (53.6%) had TAO. Age, sex and time since GH diagnosis were similar between those with and without TAO (p >= 0.300). TSI level tended to decrease with increasing time from GH diagnosis (Spearman's rho - 0.28, 95% CI - 0.43, - 0.12). TSI levels were higher among those with than those without TAO (median 4.0 vs. 2.7 IU/L, respectively, p = 0.037). There was no correlation between TSI level and inflammatory index score (rho = 0.14, 95% CI - 0.03, 0.30) or clinical severity (p = 0.527) among those with TAO. TSI level showed poor diagnostic accuracy for TAO (area under the receiver operating characteristic curve 0.60, 95% CI 0.51, 0.70). Conclusions Although Immulite (R) TSI level was higher in the presence of TAO, it showed poor diagnostic accuracy and no correlation with clinical markers of TAO severity or activity.

Automated summary

This study recruited 140 patients diagnosed with GH within the previous 12 months, with 53.6% of them having TAO. The TSI levels were higher in individuals with TAO but showed poor diagnostic accuracy and no correlation with clinical markers of TAO severity or activity.